论文部分内容阅读
目的:探讨趋化因子受体CXCR4在乳腺癌中的表达及其与临床病理学参数的关系。方法:采用半定量RT-PCR和免疫组织化学法分别检测121例乳腺癌新鲜组织及对应75例石蜡组织中CXCR4 mRNA及蛋白的表达。结果:乳腺癌中CXCR4m RNA及蛋白的表达阳性率分别为30.58%、68%;CXCR4 mRNA表达与蛋白表达呈显著正相关(χ2=5.049,P<0.05),且均与淋巴结转移关系密切,淋巴结转移阳性组CXCR4表达明显高于阴性组,差异具有统计学意义(P<0.05)。结论:CXCR4表达可能在促进乳腺癌淋巴结转移过程中起重要作用,其表达可作为判断乳腺癌恶性生物学行为并预测转移风险的一个指标,抑制CXCR4表达及其活性可为临床阻断癌细胞转移提供新的抗趋化治疗途径。
Objective: To investigate the expression of chemokine receptor CXCR4 in breast cancer and its relationship with clinicopathological parameters. Methods: The expression of CXCR4 mRNA and protein in 121 cases of breast cancer tissues and 75 cases of paraffin tissues were detected by semi-quantitative RT-PCR and immunohistochemistry respectively. Results: The positive rates of CXCR4m RNA and protein in breast cancer were 30.58% and 68%, respectively. CXCR4 mRNA expression was positively correlated with protein expression (χ2 = 5.049, P <0.05), and both were closely related to lymph node metastasis. The expression of CXCR4 in metastatic positive group was significantly higher than that in negative group (P <0.05). Conclusion: The expression of CXCR4 may play an important role in promoting lymph node metastasis of breast cancer. The expression of CXCR4 may be used as an indicator to evaluate the malignant biological behavior of breast cancer and predict the metastatic potential. Suppressing the expression of CXCR4 and its activity may block the metastasis of cancerous cells Provide a new anti-chemotaxis approach.